Dec 17,2019

Eli Lilly to Integrate Dexcom CGM into Personalized Diabetes Management System

Dexcom’s continuous glucose monitoring devices (CGMs) will be integrated with Eli Lilly and Company’s connected and disposable insulin pens as well as with the company’s pump for a hybrid closed-loop diabetes management system, the companies announced yesterday. The end goal is a personalized insulin delivery and software analysis offering that can reduce the burden for patients with Type 1 and Type 2 diabetes.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Dec 01,2019

Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)

The FreeStyle Libre is a flash glucose monitoring (FSL-FGM) system. Compared with finger-prick based self-monitoring of blood glucose, FSL-FGM may provide benefits in terms of improved glycemic control and decreased disease burden.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 01,2019

Future of information technology and telecommunication in type 1 diabetes clinical care: results of an online survey

A cross-sectional online survey in two European tertiary diabetes care centers in London, UK, and Vienna, Austria, and from online diabetes platforms was conducted. Participants were asked about general options of online diabetes care and were presented with three scenarios (teleconference, online chat and telemonitoring of continuous glucose monitoring traces). This online survey identified a highly ICT-astute group of people with type 1 diabetes, already using technology for insulin delivery, for whom online supported clinical diabetes care would be a viable and welcomed option.

CLINICAL STUDY

#cgm

#telehealth

View Analyst & Ambassador Comments
Go to original news
Dec 02,2019

Senseonics Launches Eversense CGM System with Non-Adjunctive Claim in the U.S.

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced today that Eversense users who download the new Eversense® CGM mobile app can start dosing insulin based off of the readings from their Eversense System without the need to do a confirmatory blood glucose fingerstick measurement.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 05,2019

Nemaura Medical announces expansion of SugarBEAT® offering with BEAT® Diabetes digital subscription services

Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”) announced that it has expanded its SugarBEAT® CGM capabilities by launching a new digital health offering, BEAT® Diabetes (www.BEATdiabetes.life), which focuses on the prevention and reversal of Type II diabetes through a range of holistic app and coaching services encouraging behavioural change. Both BEAT® Diabetes and SugarBEAT® target the underserved $69 billion market for Type 2 diabetics and $50 billion market for pre-diabetics.

PRODUCT

#cgm

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 17,2019

Medtronic Acquires Klue

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has completed the acquisition of Klue, a software company focused on behavior tracking that can provide real-time insights into when a person is consuming food. Klue’s technology is expected to be incorporated into the Medtronic Personalized Closed Loop (PCL) insulin pump system, currently in development.

COLLABORATION MERGERS & ACQUISITION

#product & service

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Dec 17,2019

Nemaura Medical teams up with Changing Health to battle Type 2 diabetes in UK and Ireland

Nemaura Medical Inc (NASDAQ:NMRD), the maker of the SugarBEAT continuous glucose monitor, announced Tuesday it is teaming with Changing Health to improve the management, reversal and prevention of Type 2 diabetes starting in the UK and Ireland. The partnership will utilize daily glucose trend data provided by Nemaura’s non-invasive sugarBEAT monitor, combined with Changing Health’s evidence-based digital health coaching solution.

COLLABORATION PARTNERSHIP

#product & service

#cgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Dec 20,2019

Nemaura Provides 2019 Year-End Corporate Update

Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a 2019 year-end corporate update.

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 02,2018

NYT, Bloomberg say Apple is working on Watch EKG, noninvasive glucose

Citing anonymous sources within Apple, reports in Bloomberg and the New York Times over the past weeks continue to add to the pile of leaks and rumors about two of Apple's currently under-development health devices: a wrist-worn glucose sensor and an EKG built into the Apple Watch. Combined with Apple's public efforts like the Stanford Heart study, previously documented conversations with the FDA, and participation in the FDA's pre-certification program, these efforts are starting to look like serious future products and features.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 12,2018

UnitedHealthcare, Dexcom to launch CGM pilot for Medicare Advantage members

UnitedHealthcare and Dexcom announced today at CES in Las Vegas that they will collaborate on a pilot program to provide Dexcom CGMs to UnitedHealthcare Medicare Advantage plan participants.

COLLABORATION PARTNERSHIP

#insurance

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM